Dyne Therapeutics, Inc. (DYN)
NASDAQ: DYN · Real-Time Price · USD
14.01
+0.02 (0.14%)
At close: Feb 21, 2025, 4:00 PM
13.95
-0.06 (-0.43%)
After-hours: Feb 21, 2025, 5:31 PM EST
Dyne Therapeutics Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for Dyne Therapeutics stock have an average target of 50.78, with a low estimate of 35 and a high estimate of 66. The average target predicts an increase of 262.46% from the current stock price of 14.01.
Analyst Consensus: Strong Buy
* Price targets were last updated on Jan 14, 2025.
Analyst Ratings
The average analyst rating for Dyne Therapeutics stock from 10 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 4 | 4 |
| Buy | 4 | 3 | 4 | 5 | 5 | 5 |
| Hold | 0 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 10 | 11 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Guggenheim | Guggenheim | Strong Buy Reiterates n/a | Strong Buy | Reiterates | n/a | n/a | Jan 24, 2025 |
| RBC Capital | RBC Capital | Buy Reiterates $45 | Buy | Reiterates | $45 | +221.20% | Jan 14, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $55 | Strong Buy | Reiterates | $55 | +292.58% | Jan 13, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $50 | Strong Buy | Maintains | $50 | +256.89% | Jan 10, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $55 | Strong Buy | Reiterates | $55 | +292.58% | Jan 10, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-3.53
from -3.95
EPS Next Year
-3.89
from -3.53
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | 34.4M | |||
| Avg | n/a | n/a | 6.1M | |||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -3.37 | -3.35 | -3.26 | |||
| Avg | -3.53 | -3.89 | -3.87 | |||
| Low | -3.73 | -4.53 | -4.69 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.